Medtech startup Oli adds US exec to board, VC firms promote partners
## Oli adds US medtech board member Sydney maternal health startup **Oli** appointed **Colby Holtshouse** to its board. Holtshouse was previously COO at Alydia Health before its acquisition by Organon, where she led commercialisation of a postpartum haemorrhage treatment. Oli is developing a wireless wearable for monitoring maternal and fetal signals during childbirth. The company has raised A$25 million across Series A, A2 and A3 rounds, backed by Scale Investors, Clare Ventures and the University of Sydney. Team size sits at roughly 15 people spanning clinical, engineering and commercial functions. CEO **Tara Croft** is preparing regulatory submissions to Australian and US authorities after completing pivotal trials with 1,000 mothers across seven hospitals. The appointment suggests the company is building commercial infrastructure ahead of hospital deployment. **Sales context:** Early-stage medtech companies typically hire commercial roles after regulatory approval, not before. If Oli clears regulatory hurdles, expect AE and AM positions targeting hospital procurement teams. Comp in medtech sales typically runs 60/40 base/commission split, with longer sales cycles than SaaS. ## Main Sequence promotes healthcare investor CSIRO-backed deep tech fund **Main Sequence** promoted **Dr Elaine Stead** from principal to partner. Stead has led healthcare investment strategy for 2.5 years, backing companies including Kinoxis Therapeutics and Currus Biologics. She holds a PhD in biochemistry and has a decade in venture capital. Main Sequence competes for deal flow with Blackbird, Square Peg, Airtree and OneVentures. **Sales context:** VC firms hiring partners typically expand portfolio support teams within 12-18 months. Main Sequence portfolio companies may see increased commercial advisory, which often translates to BD or partnerships roles. Entry-level BD roles at early-stage VC-backed companies in ANZ typically pay A$70k-$90k base, OTE A$110k-$140k. ## Other appointments **Aurora Labs**, the ASX-listed Perth metal 3D-printing company, made executive appointments focused on strategy and partnerships. The company reported FY2025 revenue of approximately A$744,000, indicating early commercial stage. Recent capital activity includes a A$5.5 million placement and A$1 million defence grant. **Powerhouse Venture Partners** and the **NZ Tech Institute** also announced leadership changes, though specifics on commercial roles were not disclosed. **Bottom line:** Executive movement in ANZ deep tech, venture capital and healthtech continues. For sales professionals, watch Oli's regulatory progress and Main Sequence portfolio announcements for future role openings.